Gynae

Genitourinary Syndrome of Menopause (GSM)

Creator: Dr Nadira Awal
Published: 2026-01-15

The medical name for dryness, urinary urgency and painful sex — and how well it treats.

By Dr Nadira AwalBMS Specialist3 min readMedically reviewed 9 July 2026

Folded soft blush cotton robe on warm oak with a small ceramic dish

GSM affects around 70% of post-menopausal women. Vaginal moisturisers, lubricants and low-dose vaginal oestrogen restore comfort and confidence.

Genitourinary syndrome of menopause (GSM) — the modern umbrella term that replaced ‘vaginal atrophy’ — affects up to 70% of postmenopausal women. Unlike hot flushes, which fade for most within 7–10 years, GSM is progressive: without treatment, the tissues continue to thin and symptoms almost always get worse with time. That biology is important, because it changes the treatment conversation from ‘let’s try something short-term’ to ‘this is a lifelong therapy — very like using a moisturiser on your face’. The good news is that treatment is safe, cheap, well tolerated and transformative.

What GSM actually is

A collection of vulvovaginal and lower urinary tract symptoms caused by loss of oestrogen at menopause.
The vulva and vagina, urethra, bladder trigone and pelvic floor all share the same oestrogen receptors — that is why the symptoms cluster together.
Tissues become thinner, less elastic, less vascular and less lubricated; the vaginal microbiome shifts away from protective lactobacilli, raising pH.
The condition is chronic, progressive and does not respond to systemic HRT alone in about 30–40% of women — many still need local vaginal treatment on top.

The full symptom picture

Vaginal dryness, itching, burning, soreness or a feeling of rawness.
Painful sex (dyspareunia), reduced arousal, reduced sensation, bleeding after intercourse.
Urinary urgency, frequency, nocturia, dysuria and recurrent UTIs.
Vulval fissures at the fourchette (posterior entrance) — often mistaken for thrush.
Discharge changes, malodour, and repeated ‘BV or thrush’ diagnoses that never quite settle.
Discomfort with exercise, tight clothing, wiping, or even sitting for long periods.

First-line treatments that work

Vaginal (local) oestrogen — the gold standard. Options: Vagifem/Vagirux pessaries (10 mcg), Ovestin cream, Estring (3-monthly ring), Blissel gel.
Typical regimen: nightly for 2 weeks, then twice weekly indefinitely.
Systemic absorption is negligible at standard doses — plasma oestradiol stays in postmenopausal range.
Safe alongside systemic HRT; the two do different jobs and are commonly used together.
Long-acting vaginal moisturisers (Yes VM, Regelle, Sylk, Hyalofemme) 2–3 times weekly independent of sex.
Water- or silicone-based lubricants at the moment of sex — avoid glycerin, propylene glycol and warming additives.
Pelvic floor physiotherapy for coexisting hypertonicity, prolapse or urinary symptoms.

Vagifem pessary and Ovestin cream on a bathroom shelf — Vaginal oestrogen is safe indefinitely — think of it like a moisturiser for a chronic condition, not a short course.

Beyond first-line

Prasterone (Intrarosa) — a vaginal DHEA pessary, useful when oestrogen isn’t tolerated or preferred.
Ospemifene — an oral SERM licensed for moderate-to-severe dyspareunia from GSM.
Vaginal laser and radiofrequency devices (Mona Lisa, Femilift, Votiva) — evidence still emerging; not first-line, not NHS-funded, and not a replacement for oestrogen for most women.
Testosterone can help vulval sensation and orgasm capacity when GSM has been treated but arousal remains low.

Safety questions we hear every week

Vaginal oestrogen does not need progestogen ‘cover’ at standard doses — the endometrium is not stimulated.
It is safe indefinitely — this is a chronic condition and stopping causes recurrence within weeks to months.
It is safe alongside systemic HRT — they do different jobs.
After most breast cancers, vaginal oestrogen is considered acceptable after discussion with oncology; for hormone-receptor-positive cancers on aromatase inhibitors, prasterone or non-hormonal options are often preferred, but vaginal oestrogen is not universally banned.
Any bleeding after menopause — while on vaginal oestrogen or not — needs same-week assessment.

Woman doing gentle floor-based pelvic floor exercises — Pelvic floor physiotherapy is often the missing piece when oestrogen alone hasn’t fully resolved symptoms.

What ‘good treatment’ looks like at 12 weeks

Vulval and vaginal comfort with sitting, exercise and clothing.
Sex possible and comfortable with lubricant; no bleeding.
Urinary urgency and UTI frequency reduced by 50%+.
No thrush-like symptoms; healthy pH restored.
If not: reassess dose, add pelvic floor physiotherapy, consider prasterone or ospemifene, and screen for vulval skin conditions like lichen sclerosus.

When to escalate to specialist review

Persistent pain, splitting or bleeding despite 12 weeks of adequate treatment.
White patches, tightening or architectural change of the vulva — suspect lichen sclerosus and refer.
Recurrent UTIs despite vaginal oestrogen — urology and pelvic floor review.
Any postmenopausal bleeding — same-week assessment.

Key takeaway

GSM is chronic, progressive and very treatable. Vaginal oestrogen plus a good moisturiser and lubricant transforms comfort and sex life for the vast majority of women — used long-term, not as a short course.

How Dr Awal approaches this in clinic

Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.

A detailed 60 minute first appointment — no rushed 10-minute slots.
Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
Body-identical HRT considered first-line where appropriate.
Shared-care letters sent to your NHS GP so treatment can continue affordably.
Follow-up at 3 months to fine-tune your regimen and address side effects.
Ongoing annual reviews so your plan evolves with you.

Common questions we hear about this

Do I need to be at a certain age to be seen?

No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.

Will my GP continue the prescription?

In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.

What if I've tried HRT before and it didn't suit me?

Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.

How long will I need to stay on treatment?

There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.

Where do you see patients?

All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.

About the author

Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.

Sources & further reading

General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.

Talk it through